Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vincristine sulfate liposome (Children's Oncology Group)
- Development stage
- Unknown
- Lead developer
- Acrotech Biopharma
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Vincristine sulfate liposome is a liposomal formulation of the vinca alkaloid vincristine, designed to enhance the drug's therapeutic index by prolonging circulation time and increasing delivery to tumor tissues. The active ingredient, vincristine sulfate, is encapsulated within sphingomyelin/cholesterol liposomes. Its mechanism of action involves binding to tubulin and inhibiting microtubule polymerization, which leads to mitotic arrest in metaphase and subsequent apoptosis of rapidly dividing cancer cells. In the clinical setting, specifically within the Children's Oncology Group (COG) trial AHOD0831, this formulation was evaluated as a component of the ABVE-PC chemotherapy regimen (doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide) for the treatment of newly diagnosed high-risk Hodgkin lymphoma in pediatric and adolescent patients. While the branded version, Marqibo, is FDA-approved for adult Philadelphia chromosome-negative acute lymphoblastic leukemia, its application in Hodgkin lymphoma has been primarily investigated in Phase III response-adapted therapy trials.
- Brand names
- Marqibo
- Other names
- liposomal vincristine sulfateliposomal vincristinevincristine sulfate liposome injection
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on vincristine sulfate liposome (Children's Oncology Group).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vincristine sulfate liposome (Children's Oncology Group).